Shelby Winzent-Oonk, PA-C

Publications

• Winzent-Oonk S, Staley A, Alami V, Bradley J, Harvey S, Pounds A, Kuldanek S, Pacenta H, Winters AC, McKinney C. Risk of transfusion-related iron overload varies based on oncologic diagnosis and associated treatment: Retrospective analysis from a single pediatric cancer center. Pediatr Blood Cancer. 2024 Aug 8;:e31254. [Epub ahead of print] PubMed PMID: 39118250
• Sabus A, Winzent S, Hemenway M, Levy JM, Foreman N. DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE. Neuro Oncol. 2020 Dec 4;22(Suppl 3):iii284. doi: 10.1093/neuonc/noaa222.041. PMCID: PMC7715614.
• Pacenta, H., Coughlin, R., Winzent, S., Hilden, J. M., Thornhill, D., Branchford, B. R., ... & McKinney, C. M. (2017). Optimizing Iron Overload Screening in a Pediatric Center for Cancer and Blood Disorders. Blood, 130, 2099.
• Hemenway M, Dorris K, Foreman N, Winzent S, Kissell E, Kasson J. SWK-10. Survivorship: Education, Clinical Guidelines, and Transition to Adult Care. Neuro Oncol. 2022 Jun 3;24(Suppl 1):i182–3. doi: 10.1093/neuonc/noac079.682. PMCID: PMC9165175.
• Winzent S, Dahl N, Hemenway M, Lovria R, Dorris K. OTHR-16. CONCURRENT USE OF APREPITANT AND IFOSFAMIDE IN PEDIATRIC CANCER PATIENTS. Neuro Oncol. 2020 Dec 4;22(Suppl 3):iii424. doi: 10.1093/neuonc/noaa222.637. PMCID: PMC7715537.
• Winzent-Oonk S, Vallejos C, Hemenway M, Lindsay HB, Green AL. PALC-03. MEDICAL AID IN DYING: EXPERIENCE IN THE CENTER FOR CANCER AND BLOOD DISORDERS AT CHILDREN’S HOSPITAL COLORADO. Neuro Oncol. 2024 Jun 18;26(Suppl 4):0. doi: 10.1093/neuonc/noae064.703. PMCID: PMC11183639.
• Dorris K, Mettetal A, Dahl N, Hemenway M, Winzent-Oonk S, Prince E, Vijmasi T, McWilliams J, Jordan K, Mirsky D, Hoffman L, Hankinson T. RARE-32. Phase 0 and feasibility single-institution clinical trial of intravenous tocilizumab for adamantinomatous craniopharyngioma. Neuro Oncol. 2022 Jun 3;24(Suppl 1):i17. doi: 10.1093/neuonc/noac079.057. PMCID: PMC9165090.
• Hemenway MS, Winzent-Oonk S. NURS-23. THE ROLE OF THE ADVANCED PRACTICE PROVIDER IN THE PAIRED NORMAL SPECIMEN PROCESS AT A TERTIARY CARE CENTER. Neuro Oncol. 2024 Jun 18;26(Suppl 4):0. doi: 10.1093/neuonc/noae064.671. PMCID: PMC11183424.
• Dorris K, Mettetal A, Hemenway M, Winzent-Oonk S, Dahl N, Levy JM, Prince E, McWilliams J, Jordan KR, Mirsky D, Hoffman L, Hankinson T. CP-12. PHASE 0 AND FEASIBILITY SINGLE-INSTITUTION CLINICAL TRIAL OF INTRAVENOUS TOCILIZUMAB FOR ADAMANTINOMATOUS CRANIOPHARYNGIOMA. Neuro Oncol. 2024 Jun 18;26(Suppl 4):0. doi: 10.1093/neuonc/noae064.050. PMCID: PMC11183541.
• Winzent-Oonk, Shelby & Winters, Amanda & Pounds, Aneisia & Pacenta, Holly & Levy, Jean & McKinney, Christopher. (2022). EPID-06. Transfusion related iron overload in pediatric patients with CNS tumors. Neuro-Oncology. 24. i47-i48. 10.1093/neuonc/noac079.174.
• Cho, Soohee & Miller, Kristen & Rowley, Jacqueline & Sabus, Ashley & Winzent-Oonk, Shelby & Bray, Stacy & Koo, Jane & Levy, Jean. (2022). OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy. Neuro-Oncology. 24. i147-i147. 10.1093/neuonc/noac079.542.
• Winzent-Oonk, S, Winters A, Pounds A, Pacenta H, McKinney C. Improving Screening for Transfusion Related Iron Overload in the CCBD. Poster, CHCO Quality Symposium. July 2018.
• Winzent S, Sabus A, Hemenway M, Nellan A, Mulcahy-Levy J. MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB. Neuro Oncol. 2020 Dec 4;22(Suppl 3):iii411–2. doi: 10.1093/neuonc/noaa222.578. PMCID: PMC7715474.

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Specialty Information

Specialties

• Pediatric Hematology / Oncology, Board Certification